ReviewCurrent obesity reports2026
Refining the Bariatric Journey: A Proposed Neoadjuvant and Adjuvant Framework for GLP-1 Receptor Agonists Inspired by Oncology.
Review in Current obesity reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purpose of reviewBariatric surgery is the most effective intervention for severe obesity, yet challenges such as perioperative risks in super-obesity and long-term weight regain persist. This narrative review proposes a novel multimodal framework for integrating GLP-1 receptor agonists (GLP-1 RAs) into surgical pathways. Drawing a conceptual analogy from oncologic "neoadjuvant" and "adjuvant" treatment models, we explore how pharmacotherapy can optimize surgical safety and reinforce long-term metabolic control. RECENT
findingsEmerging clinical data from prospective trials demonstrate that a short-term "neoadjuvant" course of GLP-1 receptor agonists can significantly enhance early weight loss and dyslipidemia remission without compromising perioperative safety. Conversely, retrospective analyses suggest that while preoperative weight loss is achievable, it requires careful management to mitigate potential early metabolic adaptation and prevent the "ceiling effect" on postoperative outcomes. Regarding postoperative care, recent meta-analyses confirm that adjuvant pharmacotherapy effectively addresses weight regain and sustains metabolic improvements in suboptimal responders, supporting the implementation of a structured perioperative management ladder. Obesity management is shifting from a procedure-centric approach toward a chronic, multimodal disease model. The neoadjuvant/adjuvant paradigm encourages clinicians to leverage pharmacologic tools to enhance surgical efficacy ("downstaging" risk) and prevent disease recurrence. While primarily hypothesis-generating, this framework provides a structured foundation-including a proposed perioperative management ladder-for future randomized controlled trials to establish integrated, multidisciplinary clinical standards.
Indexed as
Identifiers
42274840What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.